Prometheus and Long­board make the leap to Nas­daq with 9-fig­ure of­fer­ings and are joined by a Fal­con Edge-backed SPAC

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It’s been hard to match the whirl­wind first two months of the year in terms of IPO mo­men­tum, and March so far has been rel­a­tive­ly qui­et on that front. But that doesn’t mean com­pa­nies aren’t tak­ing the leap — now, two more biotechs and a SPAC are hop­ping aboard the train.

Fron­tier Ac­qui­si­tion, a SPAC led by Fal­con Edge Cap­i­tal’s Rick Ger­son, took home the largest raise at $200 mil­lion, fol­lowed close­ly by Prometheus Bio­sciences with $190 mil­lion. And Long­board Phar­ma­ceu­ti­cals se­cured an $80 mil­lion jump on­to Nas­daq, just over four months af­ter launch­ing out of Are­na Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER